文献速递精神分裂症与精神病性障碍

孟德尔随机化助力识别精神分裂症风险增强子RNA

Mendelian randomization facilitates identification of schizophrenia risk enhancer RNAs.
PubMed 文献 · Mol Psychiatry · 2025-11-23

研究基于BrainSeq数据构建了71,022个转录非编码增强子RNA的祖先分层eQTL图谱,整合PGC3精神分裂症GWAS与欧洲祖先eQTL进行SMR分析,识别出61个精神分裂症风险转录非编码增强子,其中19个与差异表达分析重叠,并实验验证了RGS6内含子区增强子RNA RGS6e通过反式机制调控神经相关基因表达、促进神经元分化从而降低精神分裂症风险。

要点

  • 构建了71,022个转录非编码增强子RNA的eQTL图谱,可用于增强子相关研究。
  • SMR分析识别61个精神分裂症风险转录非编码增强子,19个与差异表达重叠。
  • RGS6e增强子RNA经反式机制促进神经元分化,降低精神分裂症风险。

核心结论

  • 基于eQTL的SMR分析有助于阐明增强子及其转录产物在精神分裂症风险中的作用。
  • 转录非编码增强子eQTL图谱可应用于其他精神疾病或神经退行性疾病的增强子研究。

研究设计与样本

  • 利用BrainSeq数据构建祖先分层的71,022个转录非编码增强子RNA的eQTL图谱。
  • 整合PGC3精神分裂症GWAS与欧洲祖先人群eQTL进行基于汇总数据的孟德尔随机化(SMR)分析。
  • 结合差异表达分析并对RGS6e增强子RNA进行实验验证。

主要发现

  • 识别出61个精神分裂症风险转录非编码增强子,其中19个与差异表达分析重叠。
  • 19个重叠转录非编码增强子的差异表达效应与SMR效应呈负相关(r = -0.57,P = 0.01)。
  • 表型与基因型对转录非编码增强子表达的贡献相反(r = -0.78,P = 2.96E-3)。
  • 精神分裂症中抑制因子ZNF135水平降低,去抑制基序匹配的转录非编码增强子。
  • RGS6内含子区增强子RNA RGS6e通过反式机制调控神经相关基因表达,促进神经元分化,降低精神分裂症风险,与SMR结果一致。

临床怎么用

  • eQTL图谱与SMR分析可用于精神分裂症风险增强子及其转录产物的识别与机制研究。
  • RGS6e等增强子RNA可能为精神分裂症风险机制研究提供候选靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The transcription of enhancer RNA (eRNA) marks enhancer activity and may confer context-dependent regulatory functions, yet its underlying mechanism remains elusive. Leveraging BrainSeq data, we constructed ancestry-stratified expression quantitative trait locus (eQTL) maps for 71,022 transcriptional non-coding enhancer (TNE) RNAs. By integrating the latest Psychiatric Genomics Consortium (PGC3) schizophrenia GWAS with European-ancestry population-based eQTLs via Summary-data-based Mendelian Randomization (SMR), we identified 61 schizophrenia-risk TNEs, 19 of which overlapped with those from differential expression (DE) analysis. Intriguingly, for 19 overlapping TNEs, effects from DE analysis were inversely correlated with SMR effects (r = -0.57, P = 0.01), attributable to the opposing contributions of phenotype and genotype to TNE expression (r = -0.78, P = 2.96E-3). We further linked this discrepancy to reduced levels of the repressor ZNF135 in schizophrenia, which derepressed motif-matched TNEs. Finally, we identified and experimentally validated that an enhancer RNA within the intronic region of RGS6, termed RGS6e, regulates the expression of genes associated with the nervous system through trans-acting mechanisms, promoting neuronal differentiation and thereby reducing the risk of schizophrenia, consistent with the SMR results. This study underscores the significance of eQTL-based SMR analysis in elucidating the role of enhancers and their transcriptional products in schizophrenia risk. The eQTL map of TNEs developed in our study holds considerable potential for application in enhancer research related to other mental diseases or neurodegenerative diseases, thereby enhancing our understanding of how enhancers contribute to disease pathogenesis and progression.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Ye L, Ni C, Chen R, et al. Mendelian randomization facilitates identification of schizophrenia risk enhancer RNAs. Mol Psychiatry. 2025. PMID: 41276612. doi:10.1038/s41380-025-03358-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。